OnKure Therapeutics
Irvine, California, United States · Biopharma, Biotechnology, Healthcare
OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of best-in-class precision medicines that target biologically significant and well-validated pharmacological pathways, with a focus on oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα).
Key facts
- Headquarters
- Irvine, California, United States
- Employees
- 40
- Industries
- Biopharma, Biotechnology, Healthcare
- Status
- Private
- Website
- onkuretherapeutics.com
- Company page
Recent activity at OnKure Therapeutics
- : OnKure Therapeutics, Inc. announces presentation of clinical and preclinical data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium.
- : OnKure Therapeutics
- : OnKure, Inc. Appoints Rogan Nunn as General Counsel and Secretary
- : OnKure Announces the Appointment of Samuel Agresta, M.D., as Chief Medical Officer
- : Onkure Therapeutics Announces $54 Million Series C Financing
- : OnKure
- : OnKure, Inc.
- : OnKure, Inc.
- : OnKure, Inc.
- : OnKure, Inc.
OnKure Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Oct 2024 | Venture | $65.0M |
| May 2023 | Series C | $54.0M |
| Apr 2023 | Venture | $56.6M |
| Mar 2022 | Venture | $56.6M |
| Mar 2021 | Venture | $29.1M |
Leadership
- Anthony Piscopio, Executive Officer, Director
- Guobao Zhao, Director
- Micheal Carruthers, Director
- Isaac Manke, Director
- Andrew Phillips, Director
- Anthony Piscopio, Executive Officer, Director
- Xuedong Liu, Executive Officer, Director
- Donna Peak, Director
- Zhao Guobao, Director
- Anthony Piscopio, Executive Officer, Director
- Xuedong Liu, Executive Officer, Director
- Donna Peak, Director
Verified email and direct lines for OnKure Therapeutics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
OnKure Therapeutics in the news
- OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights - GlobeNewswire (Aug 04, 2026)
- OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies - GlobeNewswire (Mar 27, 2026)
- OnKure Therapeutics (OKUR) Stock Price, News & Analysis - MarketBeat (Oct 10, 2024)
- OnKure Therapeutics Reports First Quarter 2026 Financial Results - GlobeNewswire (May 05, 2026)
- Reneo Pharmaceuticals and OnKure Announce Proposed Merger - GlobeNewswire (May 13, 2024)
Companies similar to OnKure Therapeutics
- Terns Pharmaceuticals · Biopharma, Biotechnology, Healthcare, Pharmaceutical, Therapeutics
- HOOKIPA Pharma · Biopharma, Biotechnology, Healthcare, Pharmaceutical, Therapeutics
- Os Therapies · Biopharma, Biotechnology, Healthcare, Pharmaceutical, Therapeutics
- Lipella Pharmaceuticals · Biopharma, Biotechnology, Healthcare, Pharmaceutical, Therapeutics
- Galmed Pharmaceuticals Ltd · Biopharma, Biotechnology, Healthcare, Pharmaceutical, Therapeutics
About OnKure Therapeutics: questions and answers
What does OnKure Therapeutics do?
OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of best-in-class precision medicines that target biologically significant and well-validated pharmacological pathways, with a focus on oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα).
Where is OnKure Therapeutics headquartered?
OnKure Therapeutics is headquartered in Irvine, California, United States.
How many employees does OnKure Therapeutics have?
OnKure Therapeutics has about 40 employees.
Has OnKure Therapeutics raised funding?
Yes. Fundz has recorded 5 funding events for OnKure Therapeutics. The most recent, $65.0M, was in Oct 2024.
What is the latest news on OnKure Therapeutics?
On Nov 01, 2024, OnKure Therapeutics, Inc. announces presentation of clinical and preclinical data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy